KymaThera

KymaThera is a San Diego-based biotechnology company focused on discovering and developing next-generation precision small-molecule therapeutics for genetically defined diseases. Leveraging its proprietary structure-based drug design platform, the company designs highly selective therapies to overcome the limitations of first-generation inhibitors. KymaThera's lead candidate, K-1728, is an oral, pan-mutant selective PI3Kα inhibitor designed to target disease-driving mutations in both the kinase and helical domains while sparing wild-type PI3Kα to avoid toxicities like hyperglycemia. The company is advancing K-1728 into Phase 1 clinical development for hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer and PI3Kα-driven vascular malformations.